Clinical Trials
- Lung Cancer
Determining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer
- Date06/20/2016
- Phase 1 Cancers
A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
- Date06/16/2022
- Lung Cancer
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
- Date05/11/2022
- Bladder Cancer, Brain and Other Nervous System Cancers, Breast Cancer, Colorectal Cancer, Gynecological Cancers, Head and Neck Cancers, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Melanoma, Other Cancers, Pancreatic Cancer, Prostate Cancer, Sarcoma Cancers, Stomach and Esophagus, Thyroid and Other Endocrine Cancers, Lymphoma
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
- Ages18 years and older
- GenderBoth
- Date05/27/2022
- Breast Cancer
A Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Pretreated Metastatic Triple Negative Breast Cancer
- Date06/01/2022
- Lung Cancer
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
- Date01/14/2022
- Breast Cancer
A Safety Study of SGN-LIV1A in Breast Cancer Patients
- Ages18 years and older
- GenderFemale only
- Date06/16/2022
- Lung Cancer
A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)
- Date01/14/2022
- Lung Cancer
A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
- Date01/14/2022
- Lung Cancer
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
- Date06/06/2022